What is HC Wainwright’s Estimate for PVLA Q4 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – Investment analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Palvella Therapeutics in a research note issued on Thursday, December 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.39) for the quarter. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.12) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($2.62) EPS.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Trading Up 1.0 %

Shares of PVLA stock opened at $12.00 on Friday. The stock has a market cap of $15.84 million, a PE ratio of -0.99 and a beta of 0.61. Palvella Therapeutics has a one year low of $6.20 and a one year high of $22.32.

Insiders Place Their Bets

In related news, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the transaction, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.39% of the stock is owned by insiders.